GPT and Recurrent upper respiratory tract infections: We calculated Nfs0.05 to estimate the publication bias for each comparison and found Nfs0.05 values were greater than the number of studies except for incidence of serious adverse events, death, discontinuation, headache, upper respiratory tract infections and increased AST/ALT and CK included in the pooled analysis.